Related Experiment Videos
Future options with trastuzumab for primary systemic and adjuvant therapy
José Baselga1, Luca Gianni, Charles Geyer
1Vall d'Hebron University, Barcelona, Spain.
Seminars in Oncology
|October 19, 2004
Summary
Trastuzumab combined with chemotherapy shows promising response rates in HER2-positive breast cancer. Ongoing trials are confirming its efficacy and safety as a primary systemic therapy and in adjuvant settings.
Area of Science:
- Oncology
- Pharmacology
Background:
- HER2-positive breast cancer is linked to poorer outcomes.
- Early detection of HER2 positivity is crucial for treatment selection.
Purpose of the Study:
- To evaluate the efficacy and safety of trastuzumab as primary systemic therapy for HER2-positive breast cancer.
- To investigate the role of trastuzumab in adjuvant therapy for early breast cancer.
- To identify molecular factors influencing response and resistance to trastuzumab.
Main Methods:
- Phase II clinical trials of trastuzumab combined with taxanes and cytotoxic agents.
- Ongoing larger studies evaluating trastuzumab before and after surgery.
- Four major randomized trials assessing trastuzumab in adjuvant therapy (over 13,500 patients).
Main Results:
- Phase II trials reported pathologic complete response rates of 12%-42% and clinical complete response rates of 30%-67%.
- Favorable comparison with standard therapy in unselected breast cancer patients.
- Interim cardiac safety analyses in adjuvant trials show no concerns.
Conclusions:
- Trastuzumab demonstrates significant clinical benefit as primary systemic therapy for HER2-positive breast cancer.
- Extensive ongoing research aims to establish the definitive role, efficacy, and safety of trastuzumab in early breast cancer treatment.
- Molecular marker analysis will further refine treatment strategies.